ES2530977T3 - Método inmunoterapéutico que implica a unos anticuerpos contra el CD123 (IL-3R) y a un complejo inmunoestimulante - Google Patents

Método inmunoterapéutico que implica a unos anticuerpos contra el CD123 (IL-3R) y a un complejo inmunoestimulante Download PDF

Info

Publication number
ES2530977T3
ES2530977T3 ES11794953T ES11794953T ES2530977T3 ES 2530977 T3 ES2530977 T3 ES 2530977T3 ES 11794953 T ES11794953 T ES 11794953T ES 11794953 T ES11794953 T ES 11794953T ES 2530977 T3 ES2530977 T3 ES 2530977T3
Authority
ES
Spain
Prior art keywords
immunostimulatory complex
antibodies against
method involving
involving antibodies
immunotherapeutic method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11794953T
Other languages
English (en)
Inventor
Deborah Pauline Drane
Eugene Maraskovsky
Jefferey Stephen Boyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Ltd filed Critical CSL Ltd
Application granted granted Critical
Publication of ES2530977T3 publication Critical patent/ES2530977T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un anticuerpo o fragmento de anticuerpo que se fija selectivamente al IL-3Rα), y un complejo inmunoestimulante que comprende una saponina, un esterol y un fosfolípido, para su uso en el tratamiento de una condición de cáncer hematológico que está caracterizado por unas células que expresan el CD123 en un paciente, en donde el tratamiento comprende administrar al paciente (i) el anticuerpo o fragmento de anticuerpo que se fija selectivamente al IL-3Rα), y (ii) el complejo inmunoestimulante que comprende una saponina, un esterol y un fosfolípido.
ES11794953T 2010-06-15 2011-06-15 Método inmunoterapéutico que implica a unos anticuerpos contra el CD123 (IL-3R) y a un complejo inmunoestimulante Active ES2530977T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35498610P 2010-06-15 2010-06-15
PCT/AU2011/000725 WO2011156860A1 (en) 2010-06-15 2011-06-15 IMMUNOTHERAPEUTIC METHOD INVOLVING CD123 (IL-3Rα) ANTIBODIES AND IMMUNOSTIMULATING COMPLEX

Publications (1)

Publication Number Publication Date
ES2530977T3 true ES2530977T3 (es) 2015-03-09

Family

ID=45347584

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11794953T Active ES2530977T3 (es) 2010-06-15 2011-06-15 Método inmunoterapéutico que implica a unos anticuerpos contra el CD123 (IL-3R) y a un complejo inmunoestimulante

Country Status (7)

Country Link
US (1) US8920803B2 (es)
EP (1) EP2582390B1 (es)
AU (1) AU2011267837B2 (es)
DK (1) DK2582390T3 (es)
ES (1) ES2530977T3 (es)
PL (1) PL2582390T3 (es)
WO (1) WO2011156860A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2814962T3 (es) 2013-02-20 2021-03-29 Novartis Ag Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
PE20171764A1 (es) * 2015-01-23 2017-12-21 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123
WO2016164658A1 (en) * 2015-04-08 2016-10-13 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd123
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
CN112203725A (zh) 2018-06-13 2021-01-08 诺华股份有限公司 Bcma嵌合抗原受体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177678B1 (en) 1995-04-05 2001-01-23 Brasscorp Ltd. Method and apparatus for leak detection and non-destructive testing
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
ATE510855T1 (de) * 2000-03-06 2011-06-15 Univ Kentucky Res Found Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen
WO2003055514A1 (en) 2001-12-21 2003-07-10 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
MX2010006213A (es) 2007-12-06 2010-09-07 Csl Ltd Metodo de inhibicion de celulas madre leucemicas.

Also Published As

Publication number Publication date
AU2011267837B2 (en) 2016-06-23
PL2582390T3 (pl) 2015-05-29
EP2582390A4 (en) 2013-11-06
WO2011156860A1 (en) 2011-12-22
EP2582390B1 (en) 2014-11-19
DK2582390T3 (en) 2015-02-23
US20130149303A1 (en) 2013-06-13
US8920803B2 (en) 2014-12-30
AU2011267837A1 (en) 2013-01-10
EP2582390A1 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
ES2530977T3 (es) Método inmunoterapéutico que implica a unos anticuerpos contra el CD123 (IL-3R) y a un complejo inmunoestimulante
AR078659A1 (es) Anticuerpos monoclonales contra progastrina humana y sus usos
WO2018226578A8 (en) Nectin-4 binding proteins and methods of use thereof
AR088512A1 (es) Anticuerpos dirigidos contra el tnf
TR201905909T4 (tr) Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
BR112015032690A8 (pt) uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir crescimento tumoral e metástases
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
CO7151488A2 (es) Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos
GT200900035A (es) Anticuerpo especifico prlr y sus usos
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
ECSP13012525A (es) Anticuerpos contra metaloproteasa-9 de matriz.
CL2011002003A1 (es) Anticuerpo humanizado o fragmentos de este, que se unen al receptor del factor de crecimiento epidérmico (egfr) en una expresión aberrante o al egfr truncado ?2-7; célula huésped; composición farmacéutica que lo comprende; y su uso para tratar tratar cáncer.
CL2014001730A1 (es) Anticuerpo anti-epirregulina humanizado; vector; celula huesped; metodo de produccion; composicion farmaceutica que lo comprende; y agente terapeutico contra el cancer que lo comprende.
CL2013002203A1 (es) Molecula de union a antigeno (abm) que se une al antigeno carcinoembrionario humano (cea) unido a membrana; anticuerpo que se une a cea unido a membrana; polinucleotido que los codifica; vector; celula huesped; composicion que comprende al abm o al anticuerpo; y su uso para tratar un cancer que expresa niveles anormales de cea.
AR078693A1 (es) Vacunas dirigidas contra celulas presentadoras de antigenos
CL2012002662A1 (es) Anticuerpos bivalentes biespecificos anti-veg y un segundo sitio de unión a antígeno que se une específicamente a ang-2 humana; composicion farmacéutica que comprende dicho anticuerpo; método de tratamiento de un paciente que sufre cancer; acido nucleico codificante de dicho anticuerpo, vector de expresión y célula huesped que contiene dicho ácido nucleico.
UA106890C2 (uk) Гуманізоване антитіло до cdcp1
BR112016024214B8 (pt) Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal
CL2012002328A1 (es) Anticuerpo aislado anti-tat419 que inhibe la proliferación celular; ácido nucleico que lo codifica; célula que lo produce; método para identificar anticuerpos que unen un epítopo antigénico tat419; método para inhibir la proliferación de una célula que expresa un péptido tat419; y su uso en el tratamiento de tumores cancerígenos.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112012016742A2 (pt) metodos para tratamento de cancer pancreatico
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
BR112012022258A2 (pt) anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)
EA201690503A1 (ru) Антитела
CL2013001129A1 (es) Composicion que comprende una celula madre gbm6-ad de glioblastoma purificada; metodo de generacion de anticuerpos especificos para gbm6-ad; dicho anticuerpo; metodo para producir una vacuna de celulas dendriticas; y su uso para el tratamiento de cancer.